Clinical Trials on EGFR and/or ROS Mutant NSCLC in United Kingdom
Total 111 results
-
Massachusetts General HospitalNot yet recruitingGlioblastoma Recurrent, EGFR vIII Mutant | Newly Diagnosed Glioblastoma, EGFRvIII Mutant | Recurrent Glioblastoma, EGFR vIII NegativeUnited States
-
AstraZenecaCompletedCaucasian Patients With EGFR Mutation Positive Advanced NSCLCBulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
-
AstraZenecaNo longer available
-
Memorial Sloan Kettering Cancer CenterAstellas Pharma US, Inc.CompletedEGFR-Mutant Lung CancerUnited States
-
AstraZenecaCompletedEGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.Italy, Spain, United Kingdom, Sweden, Japan, Netherlands, Germany, France
-
Memorial Sloan Kettering Cancer CenterAstraZeneca; Genentech, Inc.CompletedNon-small Cell Lung Cancer | EGFR-mutant Lung CancersUnited States
-
Rain Oncology IncTerminatedNSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB FusionUnited States, Canada, Hong Kong
-
Sierra Oncology, Inc.TerminatedEGFR Mutated EGFR TKI Naive Metastatic NSCLCUnited States
-
Molecular Partners AGTerminatedEGFR-mutated NSCLC (Disorder)United States
-
MapKure, LLCRecruitingColorectal Cancer | Pancreatic Ductal Cancer | Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal CancersUnited States
-
University of VirginiaActive, not recruitingReal-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies (Lung001)Lung Cancer | ALK Gene Mutation | MET Gene Mutation | KRAS Mutation-Related Tumors | RET Gene Mutation | EGFR Gene Mutation | EGFR | ROS1 Gene Mutation | BRAFUnited States
-
Novartis PharmaceuticalsRecruitingAdvanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,MelanomaNetherlands, Korea, Republic of, Spain, Taiwan, Japan, Italy, Canada, United States, Singapore
-
Bridge Biotherapeutics, Inc.RecruitingEGFR Mutant Advanced Non-Small Cell Lung CancerKorea, Republic of, United States
-
J Ints BioRecruitingEGFR Mutant Advanced Non-small Cell Lung CancerKorea, Republic of, United States, Thailand
-
Blueprint Medicines CorporationActive, not recruitingNeoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Metastatic Lung Cancer | Antineoplastic Agents | Brain Metastases | Lung Neoplasm Malignant | EGFR... and other conditionsUnited States, Canada, Korea, Republic of, Japan, Taiwan
-
Taiho Oncology, Inc.RecruitingAdvanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) MutationsUnited States, Japan, Spain, Italy, Korea, Republic of, Canada, France, Australia, Germany, United Kingdom, Hong Kong, Turkey
-
Puma Biotechnology, Inc.TerminatedSolid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsFrance, United States, Spain, Belgium, United Kingdom, Serbia, Australia, Israel, Canada, Denmark, Ireland, Italy, Korea, Republic of
-
ArriVent BioPharma, Inc.RecruitingAdvanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768IUnited States, Australia, Spain, Italy, United Kingdom, France, China, Korea, Republic of, Canada, Japan, Netherlands
-
Pixium Vision SACompletedRetinitis Pigmentosa | Choroideremia | Cone Rod DystrophyAustria, Spain, United Kingdom, France, Germany
-
Scorpion Therapeutics, Inc.RecruitingNon-Small Cell Lung Cancer | NSCLC | EGFR/HER2 Exon 20 Insertion MutationUnited States, Taiwan
-
PfizerCompletedBRAF or NRAS Mutant Metastatic MelanomaUnited States, Netherlands, Italy, Germany, Switzerland
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingNSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | TNBC - Triple-Negative Breast Cancer | NSCLC Stage IV Without EGFR/ALK MutationUnited States, Canada
-
Astellas Pharma Global Development, Inc.TerminatedNon-small Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor (EGFR) MutationsUnited States
-
Palobiofarma SLOhio State UniversityActive, not recruiting
-
PfizerCompletedLocally Advanced or Metastatic NRAS Mutant MelanomaUnited States, Australia, Germany, Italy, Netherlands
-
National Eye Institute (NEI)RecruitingCone-Rod Degeneration | Rod-Cone DegenerationUnited States, Australia
-
PfizerCompletedALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLCUnited States, Canada, Australia, Taiwan, Singapore, Japan, Korea, Republic of, Spain, Belgium, Switzerland, France, Germany, Hong Kong, Italy
-
Massachusetts General HospitalNational Cancer Institute (NCI)CompletedNon-small Cell Lung Cancer Metastatic | Targetable Oncogenes (EGFR, ALK, ROS1)United States
-
Erasca, Inc.Not yet recruitingAdvanced or Metastatic NRAS-mutant MelanomaUnited States
-
AstraZenecaCompletedLocally Advanced or Metastatic NSCL Cancer Stage IIIB IVUnited Kingdom
-
SparingVisionRecruiting
-
Cancer Research UKHummingbird BioscienceRecruitingMelanoma | Cervical Cancer | Gastric Cancer | Pancreatic Cancer | Ovarian Cancer | Hepatocellular Carcinoma (HCC) | Bladder Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Castration-resistant Prostate Cancer | Non-small Cell Lung Cancer (NSCLC) | Oesophageal Cancer | RAS Wild Type Colorectal Cancer | Squamous Cell Cancer of the Head and NeckUnited Kingdom
-
AO Innovation Translation CenterTerminatedDeformity of Bone | Limb Deformities Congenital | Limb Deformities Nos (Acquired)United States, Switzerland
-
BeiGeneRecruitingLocally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2Australia, United States, Spain, France, Italy, Korea, Republic of, Poland
-
University of Colorado, DenverRecruitingNon-Small Cell Lung Cancer | ALK Gene Mutation | EGFR Gene Mutation | BRAF V600E | Non-Small Cell Carcinoma of Lung, TNM Stage 4 | ROSE Cluster 1United States
-
UCB Biopharma S.P.R.L.Pharm Research Associates (UK) Ltd.CompletedEpilepsy With POS With or Without Secondary GeneralizationDenmark, Germany, Hungary, Ireland, Italy, Netherlands, Norway, Spain, United Kingdom
-
Novartis PharmaceuticalsTerminatedCeritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (SIGNATURE)Tumors With Aberrations in ALK or ROS1United States
-
Monte Rosa Therapeutics, IncRecruitingNSCLC | Prostate Cancer | SCLC | DLBCL | High Grade Neuroendocrine Cancer | L-MYC and N-MYC Amplified Solid Tumors | NSCLC With High or Low L-MYC or N-MYC Expression | HR-positive, HER2-negative Breast CancerUnited States, Canada
-
Pasithea Therapeutics Corp.RecruitingAdvanced Solid Tumors | RAS Mutation | NF1 Mutation | RAF MutationUnited States
-
Genzyme, a Sanofi CompanyCompletedAlport Syndrome Patients With eGFR Between 45-90 ml/Min/1.73 m2France, Germany, Australia, United States, United Kingdom, Canada
-
PYC TherapeuticsRecruitingRetinitis Pigmentosa | Eye Diseases, Hereditary | Retinal Dystrophies | Retinal Dystrophy Rod | Retinal Dystrophy Rod ProgressiveUnited States, Australia
-
Advocate Health CareActive, not recruiting
-
Black Diamond Therapeutics, Inc.RecruitingNon-Small Cell Lung Cancer | NSCLC | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | EGF-R Positive Non-Small Cell Lung Cancer | Advanced Lung Carcinoma | EGFR-TKI Resistant Mutation | Advanced Non-Small Cell Squamous Lung Cancer | Epidermal Growth Factor Receptor C797S | Epidermal...Korea, Republic of, United States
-
St. Jude Children's Research HospitalNovartis PharmaceuticalsActive, not recruitingGlioma | Neoplasms | Glioblastoma | Neoplasms, Neuroepithelial | Central Nervous System Neoplasms | Brain Cancer | Brain Tumor | Ependymoma | Medulloblastoma | Anaplastic Astrocytoma | Anaplastic Ganglioglioma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Pineoblastoma | Recurrent Medulloblastoma | CNS Tumor | Pediatric... and other conditionsUnited States
-
ShireCompletedRetinopathy of Prematurity (ROP)United States, Italy, Netherlands, Poland, Sweden, United Kingdom
-
Novartis PharmaceuticalsCompletedCD79 Mutant or ABC-subtype Diffuse Large B-Cell LymphomaTaiwan, Italy, Netherlands, Hong Kong, Germany, United States, Korea, Republic of, France
-
National Eye Institute (NEI)TerminatedInherited Retinal Degeneration | Inherited Ophthalmic DiseasesUnited States
-
Massachusetts General HospitalPfizer; Array BioPharmaRecruitingNSCLC | Lung Cancer | Relapsed Cancer | Resistant Cancer | MET Amplification | Anaplastic Lymphoma Kinase Gene Translocation | ROS1 RearrangementUnited States
-
Food and Drug Administration (FDA)National Eye Institute (NEI)RecruitingAge-Related Macular Degeneration | Retinal Degeneration | Retinitis Pigmentosa | Usher Syndromes | Cone Dystrophy | Rod Dystrophy | Cone Rod Dystrophy | Hydroxychloroquine Retinopathy | Late-Onset Retinal Degeneration | Rod Cone DystrophyUnited States
-
Novartis PharmaceuticalsRecruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationItaly, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom